Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    "Cold contact urticaria"
Show Display Options
RSS Create an RSS feed from your search for:
"Cold contact urticaria"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Completed
Has Results
Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
3 Completed Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria
Condition: Cold Contact Urticaria
Intervention: Drug: Rupatadine
4 Completed The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Condition: Familial Cold Urticaria
Intervention: Drug: Kineret (anakinra)
5 Completed Bilastine Updosing - Characterization of Underlying Mechanisms
Condition: Cold Contact Urticaria
Intervention: Drug: Bilastine
6 Completed A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions
Condition: Acquired Cold Urticaria
Interventions: Drug: desloratadine;   Drug: placebo
7 Completed Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria
Condition: Urticaria
Intervention: Drug: Desloratadine
8 Completed
Has Results
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
9 Recruiting Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Condition: Urticaria
Interventions: Drug: GSK2646264 0.5% topical cream;   Drug: GSK2646264 1% topical cream;   Drug: Placebo
10 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)

Indicates status has not been verified in more than two years